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Abstract
In patients with type 2 diabetes mellitus (T2DM), the insulinotropic action of the 
GIP system is desensitized, whereas this is not the case for the GLP‐1 system. This 
has raised an interesting discussion of whether GIP agonists or antagonists are 
most suitable for future treatment of T2DM together with GLP‐1‐based therapies. 
Homozygous carriers of the GIP receptor (GIPR) variant, [E354Q], display lower 
bone mineral density, increased bone fracture risk and slightly increased blood glu-
cose. Here, we present an in‐depth molecular pharmacological phenotyping of GIPR‐
[E354Q]. In silico modelling suggested similar interaction of the endogenous agonist 
GIP(1‐42) to [E354Q] as to GIPR wt. This was supported by homologous compe-
tition binding in COS‐7 cells revealing GIPR wt‐like affinities of GIP(1‐42) with 
Kd values of ~2 nmol/L and wt‐like agonist association rates (Kon). In contrast, the 
dissociation rates (Koff) were slower, resulting in 25% higher agonist residence time 
for GIPR‐[E354Q]. Moreover, in Gαs signalling (cAMP production) GIP(1‐42) was 
~2‐fold more potent and more efficacious on GIPR‐[E354Q] compared to wt with 
17.5% higher basal activity. No difference from GIPR wt was found in the recruit-
ment of β‐arrestin 2, whereas the agonist‐induced internalization rate was 2.1‐ to 2.3‐
fold faster for [E354Q]. Together with the previously described impaired recycling 
of [E354Q], our findings with enhanced signalling and internalization rate possibly 
explained by an altered ligand‐binding kinetics will lead to receptor desensitization 
and down‐regulation. This could explain the long‐term functional impairment of the 
GIP system in bone metabolism and blood sugar maintenance for [E354Q] carriers 
and may shed light on the desensitization of the insulinotropic action of GIP in pa-
tients with T2DM.
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1 |  INTRODUCTION
Glucose‐dependent insulinotropic polypeptide (GIP) is a 
42 amino acid long peptide hormone that is secreted from 
enteroendocrine K cells located in the proximal part of the 
small intestine in response to food intake.1 As an incretin 
hormone, it stimulates insulin release after a meal; how-
ever, in contrast to glucagon‐like peptide‐1 (GLP‐1) it acts 
glucagonotropic at low blood glucose levels.2,3 GIP also 
displays a bone‐protective role as it both decreases bone 
resorption and increases bone formation.4-8 In addition, the 
use of a GIP analogue has been shown to improve bone 
strength in ovariectomized mice.9 The GIP receptor (GIPR) 
is a G protein‐coupled receptor (GPCR) belonging to sub-
class B1 of the GPCR family.10 In contrast to GLP‐1, the 
glucose‐lowering effect of GIP is impaired in patients with 
type 2 diabetes mellitus (T2DM), but the exact mechanism 
behind this remains to be described since the secretion of 
GIP seems normal or even elevated.11-14 It has been hy-
pothesized that the GIPR might be desensitized in the beta 
cells of patients with T2DM based on studies in diabetic 
rats,15 but this remains to be proven in humans. Previously 
described differences between the rodent and human GIP 
system exemplifies the necessity for studies on the human 
GIPR.16,17 Interestingly, it has been shown that the GIPR 
function in bone metabolism of patients with T2DM is not 
abolished,18 which may point towards a cell, tissue and 
possibly species‐specific down‐regulation.
Owing to the impaired insulinotropic action of GIP in pa-
tients with T2DM,11-14 the development of GIPR agonists has 
not been as successful as the development of GLP‐1 receptor 
(GLP‐1R) agonists.19,20 In fact, it has been suggested21 and also 
experimentally verified in rodents and non‐human primates22 
that GIPR antagonists are useful in the treatment of T2DM 
and obesity possibly due to a resensitization of the GIP system 
and thereby phenocopying functional agonism. However, the 
GIP system is more complex in terms of pharmacological tar-
geting. Thus, a recent phase 2 study demonstrated that a dual 
GIPR and GLP‐1R agonist provided improved glucose control 
and weight loss than therapy with a GLP‐1 agonist, suggesting 
that GIPR agonists may have a role in the treatment of T2DM 
and obesity (at least in combination with GLP‐1R agonists).23
Several naturally occurring amino acid variants of the 
GIPR have been discovered in the human population.24 The 
GIPR variant, [E354Q], is quite common with an allele fre-
quency of 0.2.25 It was described for the first time in 1998, 
where homozygous carriers of the variant were reported to 
have decreased levels in serum C‐peptide concentrations 
(14% during fasting and 11% decrease after oral glucose 
tolerance test [OGTT]).26 This was confirmed in another 
study, where homozygous carriers had slightly increased 
plasma glucose (0.15  mmol/L) 2  hours after glucose in-
gestion as well as lower insulin secretion after an OGTT.27 
In contrast to the relatively weak effect on blood glucose, 
a stronger phenotype is observed in bone homeostasis as 
homozygous carriers of GIPR‐[E354Q] have lower bone 
mineral density (BMD) and more than 50% increased frac-
ture risk.28 Several in vitro studies have been presented, 
yet with diverging results (summarized in Table 2). One 
study in Chinese hamster fibroblasts (CHL) revealed an in-
creased cAMP accumulation for [E354Q].26 Another study 
suggested decreased basal activity through Gαs in HEK293 
cells,24 whereas a third study presented no difference in 
cAMP accumulation between GIPR wt and [E354Q] upon 
expression in HEK293 cells29 or CHO cells.30 In addition, 
it has been reported that GIPR‐[E354Q] have an increased 
GIP‐induced desensitization caused by an impaired exocy-
tosis of internalized receptors.29 In the present study, we 
used in vitro and in silico methods to characterize GIPR‐
[E354Q] in terms of ligand‐receptor binding kinetics and 
receptor‐ligand interaction, signalling through different 
pathways and internalization pattern to determine whether 
any of these basic pharmacological properties could ex-
plain the altered phenotypes of persons homozygous for 
GIPR‐[E354Q]. In broader terms, studies of GIPR variants 
may contribute to an enhanced understanding of the phar-
macological potential of the GIP system and the mode‐of‐
intervention for future drugs targeting the GIPR.
2 |  MATERIALS AND METHODS
The study was conducted in accordance with the Basic & 
Clinical Pharmacology & Toxicology policy for experimen-
tal and clinical studies.31
2.1 | Materials
Human GIP(1‐42) was purchased from Bachem, Bubendorf, 
Switzerland (H5645). cDNA of human GIPR wt and GIPR‐
[E354Q] were inserted in the pCMV‐Tag2B vector. Human 
SNAP‐GIPR was ordered and synthesized by Cisbio, Codolet, 
France, and inserted in pcDNA 3.1. SNAP‐GIPR‐[E354Q] 
was created by Quick Change Mutagenesis using the prim-
ers: GGTGTCCACCAGGTGGTGTTTGC (forward) and 
GCAAACACCACCTGGTGGACACC (reverse). The 125I‐
labelled human GIP(1‐42) was purchased from PerkinElmer, 
Skovlunde, Denmark (NEX402025UC). Tag‐Lite SNAP‐
Lumi4‐Tb was purchased from Cisbio, Codolet, France 
(SSNPTBX) and Fluorescein‐O’‐acetic acid from Sigma‐
Aldrich, Broendby, Denmark (88596‐5MG‐F).
2.2 | Transfection and tissue culture
COS‐7 cells were cultured at 10% CO2 and 37°C in Dulbecco's 
Modified Eagle Medium (DMEM) 1885 supplemented 
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with 10% foetal bovine serum (FBS), 2 mmol/L glutamine, 
180 units/mL penicillin and 45 g/mL streptomycin. HEK293 
cells were cultured at 10% CO2 and 37°C in DMEM‐
GlutaMAX™‐I supplemented with 10% FBS, 180  units/
mL penicillin and 45  g/mL streptomycin. Both cell types 
were transfected using the calcium phosphate precipitation 
method.32 Transiently transfected COS‐7 cells were used in 
homologous competition binding, association and dissocia-
tion studies. Transiently transfected HEK293 cells were used 
for cAMP accumulation, β‐arrestin 2 recruitment and real‐
time internalization experiments.
2.3 | Membrane preparation
Human GIPR wt, GIPR‐[E354Q] and pcDNA3.1 membranes 
were prepared through several centrifugation steps of COS‐7 
cells expressing the corresponding receptor. The cells were 
scraped with PBS supplemented with a cOmplete™ pro-
tease inhibitor (Roche, Basel, Switzerland) and then homog-
enized using a Dounce. The homogenate was centrifuged 
for 3 minutes at 54 g (4°C), and subsequently, the superna-
tant of this homogenate was centrifuged for 45  minutes at 
21 036 g at (4°C). The pellet was resuspended in storage 
buffer (20  mmol/L HEPES buffer (pH 7.2), 0.4  mmol/L 
CaCl2, 2 mmol/L MgCl2 and cOmplete™ protease inhibitor) 
and stored at −80°C. Protein determination was performed 
according to a standard Pierce™ BCA protein assay protocol 
(Thermo Scientific).
2.4 | Homologous competition binding assay
Transiently transfected COS‐7 cells expressing either human 
GIPR wt or GIPR‐[E354Q] were seeded in clear 96‐well plates 
1 day after transfection. The number of cells added per well was 
adjusted aiming for 5%‐10% specific binding of 125I‐GIP(1‐42). 
The next day, cells were assayed by competition binding for 
3 hours at 4°C using ~15‐40 pM of 125I‐GIP(1‐42) and increas-
ing concentrations of GIP(1‐42) in binding buffer (50 mmol/L 
HEPES buffer, pH 7.2, supplemented with 0.5% bovine serum 
albumin [BSA]). After incubation, the cells were washed twice 
in ice‐cold binding buffer and lysed using 200 mmol/L NaOH 
with 1% SDS for 30 minutes. The samples were analysed by the 
Wallac Wizard 1470 Gamma Counter.
2.5 | Radioligand association and 
dissociation assay
The association assay was executed by preparing a mixture 
of 30 µg human GIPR wt, GIPR‐[E354Q] or pcDNA3.1 and 
0.5 µg wheatgerm agglutinin‐coated (WGA) PVT SPA beads 
(Perkin Elmer). This mixture was subsequently pre‐cou-
pled on a shaker in a total volume of 50 µL binding buffer 
(50  mmol/L HEPES buffer (pH 7.2), supplemented with 
1  mmol/L CaCl2, 5  mmol/L MgCl2 and 0.5% (w/v) BSA) 
for 30 minutes at 30°C. The pre‐coupling was followed by 
the distribution of membrane suspension in a CulturPlate‐96 
(Perkin Elmer, Groningen, The Netherlands) in a total vol-
ume of 90  µL binding buffer and spun down afterwards 
(1500 rpm, 5 minutes, RT). The reaction was initiated by the 
addition of ~42  pmol/L 125I‐GIP(1‐42), and the amount of 
radioligand bound to receptor was measured every minute up 
to 100 minutes at 30°C using a TopCount NXT Microplate 
Scintillation & Luminescence Counter (Packard). For the 
dissociation experiment, the membrane suspension was dis-
tributed in a total volume of 85 µL binding buffer. The mix-
ture was then pre‐incubated for 100  minutes at 30°C with 
125I‐GIP(1‐42). The dissociation was initiated by adding 
5 µL of 1 µmol/L unlabelled GIP(1‐42). The amount of ra-
dioligand bound to receptor was measured every minute up 
to 999 minutes.
2.6 | cAMP and β‐arrestin 2 assay
For the cAMP assay, HEK293 cells were transiently trans-
fected with either GIPR wt or GIPR‐[E354Q] and the bio-
luminescence resonance energy transfer (BRET) Epac‐based 
sensor for cAMP, CAMYEL (cAMP sensor using YFP‐
Epac‐RLuc).33 For the β‐arrestin 2 assay, HEK293 cells 
were transiently transfected with either GIPR wt or GIPR‐
[E354Q] and the donor Rluc8‐Arrestin‐3‐Sp1, the accep-
tor mem‐linker‐citrine‐SH3 and the GPCR kinase 2, GRK2 
to facilitate β‐arrestin 2 recruitment.34 Two days following 
transfection, the cells were washed with PBS and resus-
pended in PBS with 5 mmol/L glucose. Then, 85 µL of the 
cell suspension solution was added to each well of a black‐
white 96‐well isoplate followed by the addition of PBS with 
5 µmol/L coelenterazine‐h. Following a 10‐minute. incuba-
tion, increasing concentrations of GIP(1‐42) were added and 
incubated for an additional 30 minutes. Luminescence was 
measured by the Berthold Technologies Mithras Multilabel 
Reader (Rluc8 at 485 ± 40 nm and YFP at 530 ± 25 nm).
2.7 | Real‐time internalization assay
The assay was performed as previously described.35,36 
In short, HEK293 cells transiently expressing the human 
SNAP‐GIPR or SNAP‐GIPR‐[E354Q] were seeded in 
white 384‐well plates the day after transfection at a density 
of 25 000 cells/well. The next day, the media was removed 
and SNAP‐GIPR and SNAP‐GIPR‐[E354Q] were labelled 
with 100  nmol/L Tag‐Lite SNAP‐Lumi4‐Tb (donor) in 
OptiMEM for 60  minutes at 37°C. Afterwards, the cells 
were washed with HBBS supplemented with internaliza-
tion buffer (1 mmol/L CaCl2, 1 mmol/L MgCl2, 20 mmol/L 
HEPES and 0.1% Pluronic F‐68, pH 7.4) followed by ad-
dition of 100  µmol/L pre‐heated fluorescein‐O’‐acetic 
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acid (acceptor). The plate was placed in a 37°C incubator 
for 5  minutes prior to ligand addition to adjust the tem-
perature. Then, the cells were stimulated with 37°C pre‐
heated human GIP(1‐42) and internalization was measured 
every 3 minutes for 60 minutes at 37°C in PerkinElmer™ 
EnVision 2014 Multilabel Reader. The internalization data 
were corrected for any receptor expression differences by 
the ratio discrepancy between the two receptors.
2.8 | Molecular dynamics 
simulation of the GIPR
Since no crystal structures or cryo‐EM structures of the 
full‐length GIPR are available, a homology model of GIPR 
in complex with the naturally occurring agonist GIP(1‐42) 
was made. This chimeric homology model was assembled 
using the cryo‐EM structure of the activated GLP‐1R 37 
(residues 128‐411, PDB: 5VAI, homology  =  53%), the 
crystal structure of the extracellular domain of human 
GIPR 38 (r residues 29‐122) and the NMR solution struc-
ture of GIP(1‐42), 39 and missing residues 123‐127 were 
taken from the GPCRdb.40 Alignment of the receptor in 
the membrane was determined using the OPM database 41 
after which the receptor was inserted in a hexagonal lipid 
bilayer using the CHARMM‐GUI membrane builder con-
sisting of 150 1‐palmitoyl‐2‐oleoyl‐sn‐glycero‐3‐phospho-
choline (POPC) lipids.42 The receptor and membrane were 
dissolved in water with physiological salt concentration 
(0.15  mol/L) resulting in a system size of approximately 
80k atoms with a x/y radius of 8.5 nm and a height of 13 nm. 
The system was equilibrated in a NPT ensemble at 310 K 
for 150 ns after which it was simulated for 600 ns using the 
same ensemble and temperature with GROMACS 2018.3 
as the MD engine.43 The CHARMM36m force field was 
employed with TIP3P water molecules and a van der Waals 
cut‐off radius of 1.2 nm.44 All data analysis was performed 
using GROMACS tools and home‐made scripts. The wild‐
type snapshot in Figure 1 is taken from the MD simula-
tion. The [E354Q] image is mutated using PyMol only to 
visualize that the mutation from glutamic acid to glutamine 
allows for preservation of the hydrogen bond interaction 
between the carbonyl and N‐terminal nitrogen.
2.9 | Data and statistical analysis
Kinetic binding parameters and IC50 and EC50 values were 
determined by non‐linear regression using GraphPad Prism 7 
& 8. Sigmoid curves were fitted logistically with a Hill slope 
of 1 or −1 for the activation or binding curves, respectively. 
Internalization rates were determined by one‐phase associa-
tion analysis using GraphPad Prism 7. The observed rate 
constants Kobs (minute−1) of 125I‐GIP(1‐42) to GIPR wt and 
[E543Q] were obtained by plotting the data to a one‐phase 
association model. The dissociation rate constants Koff (min-
ute−1) were acquired by plotting data to a two‐phase decay 
model. The association rate constants for each phase Kon 
(phase) (nmol/L−1 minute−1) were calculated according to the 
following equation:
In which [L] is the ligand concentration in nmol/L. To 
correct for the one‐phase association, a single Kon (nmol/L−1  
minute−1) value, covering both phases of the dissociation rate 
(Kon (slow) and Kon (fast)), was calculated as follows:
Kon (phase)=
Kobs−Koff (phase)
[L]
F I G U R E  1  Illustration of GIPR 
wt and GIPR‐[E354Q]. The mutation of 
GIPR‐[E354Q] is located within the sixth 
transmembrane helix of the receptor. The 
genotype distribution among Europeans is 
63% wild‐type, 33% heterozygous and 4% 
homozygous25
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wherein %fast is the contribution of Koff (fast) to the associa-
tion rate constant and %slow is the contribution of Koff (slow) 
to the association rate constant. The residence time (RT) in 
minutes was acquired as follows:
EC50 and Emax values and binding parameters were com-
pared by an unpaired Student t test. Internalization rates were 
compared by a one‐way ANOVA with multiple comparisons. 
In both tests, P < .05 was considered significant different.
3 |  RESULTS
The GIPR variant [E354Q] is quite common in the human 
population with the genotype distribution of 63% wt, 33% 
heterozygous carriers and 4% homozygous carriers.25 It is 
located in the sixth transmembrane domain of the receptor 
close to the extracellular site (Figure 1). To gain understand-
ing of where in the receptor E354 is situated and what its role 
is in ligand binding, we decided to employ molecular dy-
namic (MD) simulation to study the GIPR in complex with 
the endogenous agonist GIP(1‐42). Hydrogen bond analysis 
of the MD simulations shows that the N‐terminal nitrogen 
of GIP(1‐42) forms a salt bridge with the carboxylic acid of 
E354 for approximately 78% of the simulated time indicat-
ing the importance of the interaction. The loss of the E354's 
anionic character upon mutation to a glutamine (Q) could per-
haps weaken the interaction, but will still allow for a hydrogen 
bond in the same place, which might explain why previous 
studies described only little alteration in binding affinity.24,26
3.1 | Similar binding affinity but altered 
binding kinetics of GIP(1‐42) on GIPR‐
[E354Q]
Inspired by the predicted slightly altered binding profile in 
[E354Q], we moved on with in vitro analyses of ligand bind-
ing and receptor activation. Homologous competition bind-
ing done at 4°C using 125I‐GIP(1‐42) showed no difference in 
the affinity of GIP(1‐42) to the GIPR wt and GIPR‐[E354Q] 
with Kd of 2.39 ± 0.18 and 2.08 ± 0.12 nmol/L, respectively 
(Figure 2A, Table 1). Moreover, no difference was observed 
in the Bmax values (Figure 2B). To determine whether the 
predicted altered binding mode in [E354Q] would change 
the binding kinetics, we measured association and dissocia-
tion rates of 125I‐GIP(1‐42) using membranes from COS‐7 
cells expressing either of the receptors. The experiments 
were done at 30°C, and the kinetic profiles of the association 
of 125I‐GIP(1‐42) were best fitted with a one‐phase model 
Kon=Kon (fast) ∗%fast+Kon (slow) ∗%slow
RT=
1
Koff (phase)
F I G U R E  2  Binding affinity and 
kinetics of GIP(1‐42) to GIPR wt and 
GIPR‐[E354Q]. A, COS‐7 cells were 
transiently transfected with human GIPR 
wt and GIPR‐[E354Q] and assayed for 
homologous competition binding using 
125I‐GIP(1‐42) as radioligand and increasing 
concentrations of GIP(1‐42). Data are 
normalized to the specific binding of the 
GIPR wt. B, The Bmax value was calculated 
for both GIPR wt and GIPR‐[E354Q] from 
the homologous competition binding data. 
For the association (C) and dissociation (D) 
experiments of 125I‐GIP(1‐42), membranes 
of COS‐7 cells expressing GIPR wt 
or GIPR‐[E354Q] were used. Data are 
normalized to the specific binding of each 
receptor. Data are shown as mean ± SEM, 
n ≥ 3 independent experiments carried out 
in duplicates
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with saturation reached after approximately 60 minutes for 
both receptors (Figure 2C). The observed on‐rates (Kobs) 
for GIPR wt and GIPR‐[E354Q] were 0.076  ±  0.006 and 
0.073  ±  0.011  minute−1, emphasizing that 125I‐GIP(1‐42) 
binds with similar Kobs to both receptors. After obtained 
equilibrium, we could reverse the binding of 125I‐GIP(1‐42) 
by the addition of 1 μmol/L unlabelled GIP(1‐42), and the 
corresponding dissociation profiles were best fitted with a 
two‐phase decay model with a fast and a slow phase (%fast 
phase 62% ± 2% and 64% ± 1%, respectively; Figure 2D). 
Interestingly, no complete dissociation of 125I‐GIP(1‐42) was 
obtained, as a plateau was reached at approximately 15% re-
maining 125I‐GIP(1‐42) binding on both receptors. As the off‐
rate was slower for GIPR‐[E354Q], the residence time (RT; 
defined as the reciprocal value of Koff45) of 125I‐GIP(1‐42) 
was higher than that of GIPR wt, both when calculated from 
the fast off‐rate, RT(fast) 26.41 ± 0.74 versus 33.12 ± 1.57 min 
(P = .018), and from the slow off‐rate RT(slow) 225.38 ± 3.12 
versus 267.03 ± 10.13 min (P = .017; Table 1).
3.2 | GIPR‐[E354Q] shows an increased 
cAMP signalling profile
Next, we studied whether GIPR‐[E354Q] had a different sig-
nalling pattern compared with the GIPR wt. Several studies 
have previously described diverging signalling profiles of 
GIPR wt and [E354Q].24,26,29 We decided to use same cell 
type (HEK293 cells) and same signalling principle (BRET‐
based assays) to determine signalling via G protein‐depend-
ent and ‐independent pathways in order to avoid observational 
bias. Thus, we studied both cAMP accumulation and β‐arres-
tin 2 recruitment in HEK293 cells expressing either GIPR wt 
or GIPR‐[E354Q]. GIP(1‐42) was found to be slightly more 
potent and efficacious in cAMP accumulation on GIPR‐
[E354Q] than GIPR wt with an EC50 of 0.34 ± 0.088 pmol/L 
compared with 0.69 ± 0.047 pmol/L and Emax of 137% ± 3.4% 
compared with 102% ± 1.7%, respectively (Figure 3A). In 
addition, GIPR‐[E354Q] had a higher basal cAMP activity 
than GIPR wt reaching 17.5 ± 3.0% of Emax of GIPR wt. In 
contrast, no difference was observed in the ability of the re-
ceptors to recruit β‐arrestin 2 with an EC50 of 5.5 ± 0.082 and 
4.7 ± 0.23 nmol/L and Emax of 99% ± 3.3% and 97% ± 8.6%, 
respectively, upon addition of GIP(1‐42) (Figure 3B).
3.3 | The GIPR‐[E354Q] internalizes with a 
faster rate than GIPR wt
Due to the increased cAMP accumulation for GIPR‐[E354Q], 
we went on and studied whether GIPR‐[E354Q] had an al-
tered internalization pattern. Again, we used HEK293 cells. 
In order to measure the internalization in real‐time, we used 
SNAP‐tagged versions of both receptors. Since internaliza-
tion is very dependent on receptor expression,36 the inter-
nalization data were corrected for any receptor expression 
differences measured by the donor signal. Both receptors 
were internalized after stimulation with 100  nmol/L and 
1  µmol/L GIP(1‐42) (Figure 4A‐C); however, the GIPR‐
[E354Q] displayed faster internalization than GIPR wt at 
both 100 nmol/L and 1 µmol/L GIP(1‐42) stimulation with 
the values of 0.086  ±  0.030 and 0.094  ±  0.011 compared 
with 0.037 ± 0.011 and 0.045 ± 0.006 minute−1, respectively. 
Notably, no statistical significant differences were observed 
in the internalization efficacy between the two receptors 
(bsAUC for 100 nmol/L GIP(1‐42) stimulation: 61 ± 8.0 and 
76 ± 45 for GIPR wt and GIPR‐[E354Q], respectively, and 
T A B L E  1  Binding parameters of 125I‐GIP(1‐42) to GIPR wt and 
GIPR‐[E354Q]
  GIPR wt GIPR‐[E354Q]
KD (nmol/L) 2.39 ± 0.18 2.08 ± 0.12
Kobs (min−1) 0.076 + 0.006 0.073 ± 0.011
Koff (fast) (min−1) 0.034 ± 0.006 0.030 ± 0.007
Koff (slow) (min−1) 0.0044 ± 0.0001 0.0038 ± 0.0002
% fast phase 62 ± 2 64 ± 1
RT(fast) (min) 26.41 ± 0.74 33.12 ± 1.57*
RT(slow) (min) 225.38 ± 3.12 267.03 ± 10.13*
Kon (nM−1 * min−1) 1.283 ± 0.253 1.371 ± 0.378
Note: The residence times were compared by an unpaired Student t test 
(*P < .05).
F I G U R E  3  Human GIP(1‐42) 
concentration curves for cAMP 
accumulation and β‐arrestin 2 recruitment. 
HEK293 cells were transiently transfected 
with GIPR wt or GIPR‐[E354Q] and (A) 
the Epac‐based BRET sensor CAMYEL for 
cAMP accumulation or (B) the donor Rluc8‐
Arrestin‐3‐Sp1, the acceptor mem‐linker‐
citrine‐SH3 and the GPCR kinase 2 (GRK2) 
for β‐arrestin 2 recruitment. Data are 
shown as mean ± SEM, n = 3 independent 
experiments carried out in duplicates
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bsAUC for 1  µmol/L GIP(1‐42) stimulation: 97  ±  5.1 and 
79 ± 55 for GIPR wt and GIPR‐[E354Q], respectively).
4 |  DISCUSSION
Our study demonstrates that the naturally occurring GIPR var-
iant, [E354Q], that results in long‐term impairment of the GIP 
system in humans and markedly increased fracture risk,28 dis-
plays an altered molecular pharmacological phenotype com-
pared with wt receptor. We find an enhanced internalization 
rate possibly explained by an altered ligand‐binding mode, 
enhanced residence time and enhanced downstream signal-
ling of the endogenous agonist GIP(1‐42). Together with the 
previously described impaired recycling of [E354Q],29 these 
findings suggest facilitated receptor desensitization and long‐
term down‐regulation. This is highly relevant, as the GIP sys-
tem seems more prone to desensitization as compared to the 
GLP‐1 system given the decline in the insulinotropic action of 
GIP (but not of GLP‐1) over time in patients with T2DM.11-14 
Thus, the phenotype of [E354Q] may represent the end‐stage 
activity of the ‘normal’ wt GIP system in T2DM and obesity 
where hyperglycaemia and enhanced levels of GIP may have 
contributed to receptor desensitization.
4.1 | GIP(1‐42) shows altered efficacy and 
residence time on GIPR‐[E354Q]
The residence time, that is the time in which a drug remains 
bound to its target, has become increasingly acknowledged as 
an important parameter in pharmacology due to its strong pre-
dictive value for in vivo pharmacological activity.45 The longer 
a certain drug occupies a receptor, the more profound effect 
is obtained, thus a higher efficacy may be reached.46 This has 
for instance been shown for the β2‐adrenoceptor agonist, C26, 
having a longer residence time and higher potency and effi-
cacy in several distinct signalling pathways compared with the 
endogenous agonist adrenaline.47 Furthermore, it has been 
shown for three adenosine A1 receptor (A1R) agonists, all 
having similar affinity, but different binding kinetics, where 
the agonist (LUF6941) with the longest residence time had 
the greatest anti‐lipolytic effect in rat adipocytes.48 We found 
that GIP(1‐42) bound with the same affinity to GIPR wt and 
GIPR‐[E354Q] (Figure 2A). Looking further into the ligand‐
binding kinetics, no differences were observed in the associa-
tion rates, but the dissociation was slower for GIP(1‐42) on 
GIPR‐[E5354Q], which in turn revealed a higher residence 
time for the agonist binding to the this receptor (Table 1). 
This aligns very well with the enhanced cAMP activity ob-
served for GIPR‐[E354Q] (Figure 3A), that, however, stands 
in contrast to a previous study describing the opposite (de-
creased cAMP) in HEK293 cells for GIPR‐[E354Q].24 This 
difference could be due to assay technicalities, as we used 
real‐time cAMP measurements, whereas the luciferase re-
porter gene assay used in Ref24 represents a downstream 
end‐point cAMP measurement. Given the faster internaliza-
tion of GIPR‐[E354Q] (Figure 4B,C) and previously pub-
lished decreased recycling leading to faster desensitization, 
it is likely that an end‐point measurement will reveal overall 
lower activity levels for GIPR‐[E354Q] as compared to wt 
receptor. Table 2 provides a comprehensive overview of our 
data of GIPR‐[E354Q] in comparison with previously pub-
lished data.
4.2 | High potency for agonist‐induced 
cAMP accumulation relative to arrestin 
recruitment and affinity
Pharmacological characterizations of ligands for GPCRs in-
clude determination of affinity under equilibrium conditions 
(eg the IC50 value or KD) and signalling activity (potency 
(EC50) and efficacy (Emax)).45 We observed a huge prefer-
ence towards G protein activation compared with arrestin 
recruitment with 8000‐ to 14  000‐fold higher potency of 
F I G U R E  4  Internalization of SNAP‐GIPR wt and SNAP‐GIPR‐[E354Q]. HEK293 cells were transiently transfected with SNAP‐GIPR (A) 
or SNAP‐GIPR‐[E354Q] (B) and assayed for internalization over time following stimulation of 100 nmol/L (■) or 1 μmol/L (●) GIP(1‐42). (C) A 
zoom of the first 25 min of internalization of SNAP‐GIPR and SNAP‐GIPR‐[E354Q] following 1 μmol/L GIP(1‐42) stimulation. Data are shown as 
mean ± SEM, n = 3 independent experiments carried out in triplicates
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GIP(1‐42)‐induced cAMP accumulation in the two GIP recep-
tors (Figure 3). This is in accordance with our previously pub-
lished potency differences for the GIP receptor 35 and for the 
closely related GLP‐1 receptor.49,50 The same pattern was ob-
served for the glucagon receptor (GCGR), though with a less 
pronounced difference.49 A contributing factor to the higher 
potency observed for class B1 receptors to induce cAMP ac-
cumulation could be downstream amplification of Gαs which 
is not the case for β‐arrestin recruitment and internalization. 
However, as other Gαs‐coupled receptors, such as class A re-
ceptors, like the adrenergic receptors do not display such bias 
towards Gαs over arrestin recruitment, it could also reflect 
that Gαs is the main signalling pathway during physiological 
control. A similar difference (3000‐6000‐fold) was observed 
when comparing the nanomolar binding affinity (KD) to the 
picomolar potency (EC50) in cAMP accumulation, again, a 
general tendency for ligands of class B GPCRs51,52 and a phe-
nomenon that ensures receptor signalling even with very little 
occupancy. This suggests the presence of spare receptors, that 
is a surplus of receptors relative to the occupancy needed for 
signalling output,53 and could reflect the high importance of 
receptor signalling in human health (such as blood glucose 
regulation among other roles for the incretin receptors). It 
is, however, also likely that the downstream amplification of 
cAMP contributes to the potency:affinity difference.
4.3 | GIPR desensitization and signalling 
from endosomes
It is well known that the insulinotropic action of GIP is dimin-
ished in patients with T2DM11-14; however, the exact mecha-
nism for this is not known. Maintained high plasma levels of 
GIP in patients with T2DM exclude lack of ligand to explain 
the diminished effect.54 It has, however, been suggested that 
an increased GIPR desensitization in the beta cell could be 
involved in the impaired response of GIP to hyperglycaemia 
in patients with T2DM (as reported in diabetic rats15) or that 
downstream GIPR signalling is altered in the beta cells.55 
We have previously shown that the GIPR internalizes in a 
low‐potent, β‐arrestin‐dependent manner with equal impor-
tance of β‐arrestin 1 and β‐arrestin 2 and only minimum 
internalization in the absence of arrestins.35 The low‐potent in-
ternalization observed for GIPR and for other class B GPCRs 
thus aligns well with the low‐potent β‐arrestin recruitment 
for these receptors as observed in for instance the GLP‐1R 
and the GCGR.50,56 Here, we describe that the GIPR variant 
[E354Q] internalizes faster than the wt receptor (Figure 4B) 
possibly caused by altered agonist binding mode and kinetics 
with the increased residence time of the agonist (and a subse-
quent higher cAMP‐mediated signalling which for the GIPR 
has been reported to also occur intracellularly from GIPR ex-
pressed in endosomes57). Together with the reported impaired 
exocytosis of GIPR‐[E354Q],29 the increased internalization 
will contribute to receptor desensitization and down‐regu-
lation over time (Figure 5). Thus, the impaired recovery of 
GIPR‐[E354Q] may over time lead to an impaired response of 
GIP resulting in the altered bone homeostasis and blood glu-
cose control in E354Q carriers. This resembles the suggested 
desensitization of the wt GIP system in patients with T2DM, 
and it can therefore be hypothesized that the increased desen-
sitization of GIPR‐[E354Q] mimics what happens over time 
in T2DM and that studies of the GIPR‐[E354Q] signalling 
might contribute to a better understanding of the decreased 
sensitivity of the wt GIP system in T2DM.
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F I G U R E  5  Illustration of altered signalling mechanism of GIPR‐[E354Q] and possible link to long‐term consequences
Basic pharmacological properties of GIPR-[E354Q] 
- Enhanced agonist residence time
- Enhanced cAMP  signaling from
cell surface and endosomes
- Maintained β-arrestin recruitment
- Enhanced internalization rate and
- Decreased recycling to cell surface
Cellular effects
 - Receptor desensitization
- Receptor down-regulation
Altered phenotype in human carriers of E354Q
 - Decreased bone strength and increased fracture risk
- Slightly impaired blood glucose control
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